Gene Therapy Reaches XLRS Milestone - Summary - MDSpire

Gene Therapy Reaches XLRS Milestone

Atsena Therapeutics reports positive interim data for XLRS gene therapy

  • May 25, 2026

  • 3 min

Share

Objective:

To evaluate the safety and efficacy of ATSN-201, an investigational gene therapy for X-linked retinoschisis (XLRS), in a clinical trial.

Key Findings:
  • Structural and functional improvements were observed in treated adults.
  • Foveal schisis closure was confirmed in four of six treated adults in Cohort 4.
  • No serious adverse events were reported across all cohorts.
Interpretation:

Limitations:
  • The study included a small sample size of nine adults and three pediatric patients.
  • Control patients may receive treatment after one year of observation, which could affect outcomes.
Conclusion:

Original Source(s)

Gene Therapy Reaches XLRS Milestone

  • May 25, 2026

Related Content

FDA Clears Nocturnal IOP Device

Balance Ophthalmics gains FDA 510(k) clearance for wireless FSYX glaucoma device

  • May 26, 2026

  • 2 min
Refocusing Retinal Imaging

New study looks at extending retinal focus using computational adaptive optics framework

  • May 26, 2026

  • 4 min
"All Eyes on DME"

Genentech launches diabetic macular edema awareness campaign fronted by actor and comedian, Damon Wayans

  • May 22, 2026

  • 3 min